Victoria Potoupni

Dr. Victoria Potoupni

orcid

Research Focus & Metrics

Academic Career Length

2Years (2025-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
29 October 2025 in Medicina
Verified
Journal Article
Open access
PDF file
VPVictoria Potoupni
Victoria Potoupni
Athanasios SamarasAthanasios Samaras
Athanasios Samaras
CPChristodoulos Papadopoulos
Christodoulos Papadopoulos
ABAristi Boulmpou
Aristi Boulmpou
TMTheodoros Moysiadis
Theodoros Moysiadis
VVVasileios P. Vassilikos
Vasileios P. Vassilikos
Heart failure with preserved ejection fraction (HFpEF) remains a major clinical challenge due to its heterogeneous presentation and limited therapeutic options. Accurate patient phenotyping is essential to improve diagnosis, prognostication, and treatment personalization. Machine learning (ML) has emerged as a powerful tool to identify clinically meaningful HFpEF subgroups by integrating diverse data sources, including clinical, imaging, biomarker, and physiological parameters. ML-based models can uncover subtle patterns not captured by traditional methods, offering improved risk stratification, earlier intervention, and guidance toward individualized therapy. Future progress will rely on standardized data collection, validation across populations, and incorporation into clinical decision support systems. Advancements in explainable artificial intelligence, federated learning, and multi-omics integration are expected to further refine phenotyping strategies and translate into improved patient outcomes. Continued interdisciplinary collaboration is essential to unlock the full potential of ML in transforming HFpEF management.

29 September 2026 in Hellenic Journal of Cardiology
Verified
Journal Article
Open access
LRLOUKIANOS RALLIDIS
LOUKIANOS RALLIDIS
DTDonatos Tsamoulis
Donatos Tsamoulis
DBDespoina-Rafailia Benetou Benetou
Despoina-Rafailia Benetou Benetou
VBVasileios Bouratzis
Vasileios Bouratzis
MPMichail Papapanou
Michail Papapanou
CVCharalambos Vlachopoulos
Charalambos Vlachopoulos

6 September 2026 in Clinical Cardiology
Verified
Journal Article
Open access
VPVictoria Potoupni
Victoria Potoupni
ABAristi Boulmpou
Aristi Boulmpou
SMSpyridon Maragkoudakis
Spyridon Maragkoudakis
Alexandros BriasoulisAlexandros Briasoulis
Alexandros Briasoulis
EFEMMANOUIL FOUKARAKIS
EMMANOUIL FOUKARAKIS
CPChristodoulos Papadopoulos
Christodoulos Papadopoulos
Introduction: Heart failure with reduced ejection fraction (HFrEF), defined by a left ventricular ejection fraction ≤ 40%, remains a major global health challenge, associated with substantial morbidity, mortality, and impaired quality of life (QoL), particularly in patients with higher NYHA class. Sodium–glucose cotransporter‐2 (SGLT2) inhibitors have emerged as a cornerstone therapy for HFrEF, significantly reducing hospitalizations and mortality regardless of glycemic status, sex, race, or comorbidities. Methods: EVOLUTION‐HF was an observational, multi‐center, longitudinal cohort study involving 257 consecutive patients diagnosed with HFrEF who initiated dapagliflozin in a routine clinical setting in Greece. The primary objectives were to characterize baseline demographic and clinical features of patients newly initiated on dapagliflozin for HFrEF and to evaluate dapagliflozin treatment patterns, including discontinuation timing, reasons for discontinuation, and concomitant heart failure and glucose‐lowering therapies over time. The secondary objectives are to describe patient‐reported outcomes using the KCCQ‐23 and to assess adherence to dapagliflozin among patients with HFrEF. Results: A total of 257 patients were enrolled and the follow‐up period lasted for 12 months. Significant improvements among all KCCQ‐23 scores were observed from baseline to 12‐months post dapagliflozin initiation, revealing that the initiation and optimization of guideline‐directed medical therapy in routine clinical practice provides improvement to quality of life over time. Conclusions: Dapagliflozin was safe and well‐tolerated throughout the observation period. Although benefits are observed in most patients, individuals aged > 65 years, with prior myocardial infarction, or recent hospitalizations show a diminished response, underscoring the need for tailored management and closer follow‐up in these higher‐risk groups.